芳香单环类衍生物及其制备方法和用途
By preparing aromatic monocyclic derivative compounds, the problem of the lack of selective RAC1 drugs in the market has been solved, enabling effective treatment of RAC1-mutant diseases, especially melanoma, and meeting clinical needs.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- ZHEJIANG HISUN PHARMA CO LTD
- Filing Date
- 2023-03-24
- Publication Date
- 2026-07-17
AI Technical Summary
Currently, there is a lack of selective drugs targeting RAC1 on the market, especially for melanoma with RAC1 P29S mutations, for which there are no available targeted therapies. Furthermore, RAC1 is abnormally expressed in various cancers, indicating significant clinical demand and market potential.
An aromatic monocyclic derivative is provided for the preparation of RAC1 inhibitors by means of compounds of general formula (I), (II), (III) or (IV) or their stereoisomers, tautomers or pharmaceutically acceptable salts, for the treatment of diseases mediated by RAC1 mutations such as cancer, Menx disease, rheumatoid arthritis, atherosclerosis, diabetes (type I) and Alzheimer's disease.
It achieves selective inhibition of RAC1, has broad therapeutic potential, and provides new treatment options, especially for melanoma with RAC1 P29S mutations, meeting clinical needs.
Smart Images
Figure CN117551078B_ABST